Prosensa – Dutch biotech success

Prosensa is a succesful biotech company in the Dutch Life Sciences Cluster. In January 2012 it closed the Series C round and raised another $30 million, by a large international investor.  Prosensa has grown from a small startup to a renowned Dutch biotech company in the development of a treatment from “bench to bed” for orphan diseases.

Partner The Decision Institute has written a Harvard Style Business Case about the company and its search for a treatment for Duchenne Muscular Dystrophy, a rare genetic disorder. The objective is to demonstrate the best practices of the Dutch biotech cluster. What can we learn from Prosensa and the biotech cluster? What are their strategies to bind large investors? Thanks to Leiden University, LSH, LUMC, NGI, PGGM, Prosensa, The Decision Institute and expecially all interviewees and editors who made it possible to develop the The Prosensa Case; Pioneering & Partnering. The case and the experiences of The Decision Group can help you to bind international partnerships for your strategic next steps.  

Biotech and The Decision Group.

Since 1998,  extensive expertise is built in biotech and life sciences. Out portfolio contains a wide range of projects for big pharma, medical device companies and biotech companies. Scenario analysis and strategic reviews as well as helping  to create patient centered relations with customers and realizing growthpotential in the cost-cutting market..
Furthermore, The Decision Group monitors clusters success in Life Sciences & Health. The Dutch Life Sciences & Health Outlook measures performance and progress of the industry and benchmarks with succesful clusters worldwide. The aim of the Outlook 2013 is also to address the convergence to healthcare. Innovation from Bench to Bed.

  • Learn more on scenario planning and cluster monitoring by visiting the website advanced strategic tools.
  • Request your copy of the Dutch Life Sciences Outlook here.
  • Send an e-mail to Kim Bruheim to learn more on the possibilities with the new case.
  • See also:

The Decision Group:
Consulting on Competitiveness & Clusters
Consulting on Life Sciences
Dutch Life Science Outlook

The Decision Institute: Clusters and Competitiveness:
The Netherlands Institute of Competitiveness
Microeconomics of Competitiveness

Executive programs:
Strategy & Governance Excellence Series

Comments are closed.